Company (NASDAQ: CLPT) insider plans sale of 20,000 common shares
Rhea-AI Filing Summary
A holder of CLPT common stock has filed a notice of intent to sell 20,000 common shares, to be executed through Morgan Stanley Smith Barney LLC on or around 01/09/2026 on NASDAQ, with an indicated aggregate market value of $306,200.00 and total shares outstanding of 28,423,308.
The shares to be sold were acquired on 01/09/2026 by exercising stock options for cash. The notice also reports that, during the prior three months, a Rule 10b5-1 trading plan for the Joseph M. Burnett Trust dated 10/20/2022 sold 26,463 common shares on 10/10/2025 for gross proceeds of $714,032.60. The signer represents that they do not know of any undisclosed material adverse information about CLPT’s current or prospective operations.
Positive
- None.
Negative
- None.
FAQ
How many CLPT common shares are planned for sale in this Form 144?
The notice covers a proposed sale of 20,000 shares of common stock, to be sold through Morgan Stanley Smith Barney LLC on NASDAQ.
What is the approximate value of the CLPT shares to be sold?
The planned sale of 20,000 common shares has an indicated aggregate market value of $306,200.00 as disclosed in the filing.
How and when were the CLPT shares being sold acquired?
The 20,000 common shares were acquired on 01/09/2026 through an exercise of stock options, with the purchase price paid in cash on the same date.
What prior CLPT share sales are disclosed for the last three months?
The filing reports that a Rule 10b5-1 plan for the Joseph M. Burnett Trust dated 10/20/2022 sold 26,463 common shares on 10/10/2025 for $714,032.60 in gross proceeds.
How many CLPT shares are reported as outstanding in this notice?
The securities information section states that there are 28,423,308 common shares outstanding at the time referenced in the notice.
What representation does the seller make about CLPT’s non-public information?
By signing the notice, the person for whose account the securities are to be sold represents that they do not know any material adverse information about CLPT’s current or prospective operations that has not been publicly disclosed.